PB1779: DEVELOPING NOVEL SYNERGISTIC DRUG COMBINATIONS WITH VENETOCLAX IN ACUTE MYELOID LEUKAEMIA

PB1779: DEVELOPING NOVEL SYNERGISTIC DRUG COMBINATIONS WITH VENETOCLAX IN ACUTE MYELOID LEUKAEMIA

Bibliographic Details
Main Authors:	R. Harrigan, E. Johnston, K. Matchett, T. Bjourson
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000849968.14914.70

Similar Items

Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells
by: Hyunsoo Cho, et al.
Published: (2021-04-01)

Long‐term remission of extramedullary cutaneous relapse of acute myeloid leukaemia (leukaemia cutis) treated with decitabine‐venetoclax
by: Denise Maravalle, et al.
Published: (2022-05-01)

PB1817: THE ADDITION OF ZALCITABINE TO ACUTE MYELOID LEUKEMIA TREATMENT MAY IMPROVE AZACITIDINE AND VENETOCLAX COMBINATION
by: Álvarez-Galeano Sofía, et al.
Published: (2023-08-01)

PB1840: MONOCENTRIC EXPERIENCE OF VENETOCLAX-BASED REGIMENS FOR ACUTE MYELOID LEUKEMIA
by: M. Sciumè, et al.
Published: (2022-06-01)

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies
by: Mila S. Griffioen, et al.
Published: (2022-07-01)

PB1885: PHASE 1 STUDY OF ZIFTOMENIB IN COMBINATION WITH VENETOCLAX, VENETOCLAX/AZACITIDINE, OR STANDARD INDUCTION (7 + 3) CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
by: Amer M Zeidan, et al.
Published: (2023-08-01)

Multiplex Screening for Interacting Compounds in Paediatric Acute Myeloid Leukaemia
by: Lauren V. Cairns, et al.
Published: (2021-09-01)

Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate
by: Renshi Kawakatsu, et al.
Published: (2024-02-01)

PB1877: EFFECTS OF VENETOCLAX-BASED COMBINATIONS FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA IN CLINICAL SETTINGS
by: Young Seob Park, et al.
Published: (2023-08-01)

PB1872: SELINEXOR IN COMBINATION WITH VENETOCLAX AND HYPOMETHYLATING AGENTS FOR ACUTE MYELOID LEUKEMIA PATIENTS WITH SEVERE CO-MORBIDITIES
by: Fangli Chen, et al.
Published: (2023-08-01)

Combination strategies to overcome drug resistance in FLT+ acute myeloid leukaemia
by: Jingmei Yang, et al.
Published: (2023-08-01)

Venetoclax Resistance in Acute Myeloid Leukemia
by: Sylvain Garciaz, et al.
Published: (2024-03-01)

Venetoclax in adult acute myeloid leukemia
by: Mengci Hu, et al.
Published: (2023-12-01)

A Combined Histone Deacetylases Targeting Strategy to Overcome Venetoclax Plus Azacitidine Regimen Resistance in Acute Myeloid Leukaemia: Three Case Reports
by: Bin-Ru Wang, et al.
Published: (2021-12-01)

PB1871: HIGH RATES OF INFECTION AND RELATED MORALITY FROM VENETOCLAX THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKAEMIA: A SINGLE CENTRE RETROSPECTIVE STUDY
by: Durga Chandran, et al.
Published: (2023-08-01)

Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid Leukemia
by: Emmanuella Oyogoa, et al.
Published: (2023-07-01)

PB1862: VENETOCLAX AND AZACITIDINE THERAPY IN ACUTE MYELOID LEUKEMIA PATIENTS WITH SEVERE RENAL IMPAIRMENT
by: Ryosuke Naka, et al.
Published: (2023-08-01)

Venetoclax-containing regimens in acute myeloid leukemia
by: Ibrahim Aldoss, et al.
Published: (2021-02-01)

PB1857: VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IN OLDERLY OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
by: Xiao Han, et al.
Published: (2023-08-01)

Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia.
by: Farhat L Khanim, et al.
Published: (2009-12-01)

Venetoclax Combination Treatment of Acute Myeloid Leukemia in Adolescents and Young Adult Patients
by: Elena Chatzikalil, et al.
Published: (2024-04-01)

P476: AN ORAL COMBINATION THERAPY OF OR-2100 AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA
by: Kazuharu Kamachi, et al.
Published: (2023-08-01)

Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
by: Bachar Samra, et al.
Published: (2020-11-01)

Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America
by: Andrés Gómez-De León, et al.
Published: (2022-12-01)

PB1757: NOVEL THERAPEUTIC STRATEGY TARGETING CELLULAR REDOX SYSTEMS USING DIMETHYL FUMARATE AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA
by: Shin-Ichiro Kawaguchi, et al.
Published: (2023-08-01)

PB1861: EFFICACY AND TOXICITY OF VENETOCLAX PLUS HYPOMETHYLATING AGENTS IN THE REAL LIFE OF ACUTE MYELOID LEUKEMIA
by: Gianluca Martini, et al.
Published: (2023-08-01)

P547: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH ACUTE MYELOID LEUKAEMIA TREATED WITH VENETOCLAX COMBINATION THERAPY: REAL-WORLD EXPERIENCE IN BOTH FRONTLINE AND RELAPSED/REFRACTORY SETTINGS
by: H. P. J. Lam, et al.
Published: (2022-06-01)

Outcomes of venetoclax combined with homoharringtonine and cytarabine in fit adults patients with de novo adverse‐risk acute myeloid leukaemia: A single‐centre retrospective analysis
by: Bao‐Quan Song, et al.
Published: (2023-11-01)

Acute Myeloid Leukaemia with Plasmacytosis
by: Yasmin Akhtar, Saqib Qayyum Ahmad, Shahid Jamal
Published: (2016-12-01)

Exploring the acute myeloid leukaemias
by: TB Thapa
Published: (2013-10-01)

Oridonin Synergistically Enhances the Pro-Apoptotic Effect of Venetoclax on Acute Myeloid Leukemia Cells by Inhibiting AKT Signaling
by: Lin Chen, et al.
Published: (2023-09-01)

Abivertinib synergistically strengthens the anti‐leukemia activity of venetoclax in acute myeloid leukemia in a BTK‐dependent manner
by: Shujuan Huang, et al.
Published: (2020-10-01)

PB1792: REPURPOSING OF ANTIBIOTICS INHIBITING MITOCHONDRIAL TRANSLATION IN COMBINATION WITH VENETOCLAX IN ACUTE MYELOID LEUKEMIA: FROM PRECLINICAL MODELS TO CLINICAL PRACTICE
by: Viviana Amato, et al.
Published: (2023-08-01)

Biomarkers of Response to Venetoclax Therapy in Acute Myeloid Leukemia
by: Carlos Rodríguez-Medina, et al.
Published: (2024-01-01)

Secondary acute myeloid leukaemia in children treated for acute lymphoblastic leukaemia.
by: Eden, O, et al.
Published: (1998)

THE GROWING ROLE OF THE BH3 MIMETIC DRUG VENETOCLAX IN THE THERAPY OF ACUTE MYELOID LEUKEMIA
by: Elvira Pelosi, et al.
Published: (2022-10-01)

The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia
by: Byungho Lim, et al.
Published: (2022-04-01)

Advancing the standard: venetoclax combined with intensive induction and consolidation therapy for acute myeloid leukemia
by: Curtis A. Lachowiez, et al.
Published: (2022-04-01)

Harnessing the graft-versus-leukaemia effect in acute myeloid leukaemia
by: Sweeney, C
Published: (2021)

Mortality in paediatric acute myeloid leukaemia
Published: (2020-10-01)